Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IAPP | P10997 | 4/20 | 0.49 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.35 |
| ▸ | F2RL1 | P55085 | 1/20 | 0.34 |
| ▸ | TBXAS1 | P24557 | 3/20 | 0.33 |
| ▸ | ESR1 | P03372 | 1/20 | 0.33 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | HMOX1 | P09601 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4906214 | 0.79 | ALDH1A1 (0.52) | IAPPHCAR2TBXAS1ESR1CYP19A1 | |
| SCHEMBL12530406 | 0.78 | TBXAS1 (0.57) | TDP1TBXAS1ESR1CYP19A1L3MBTL1 | |
| Hydrochloric Acid SCHEMBL10770836 | 0.78 | ALDH1A1 (0.50) | IAPPHCAR2TBXAS1ESR1CYP19A1 | |
| SCHEMBL7011872 | 0.77 | KEAP1 (0.52) | HCAR2TBXAS1 | |
| SCHEMBL7178176 | 0.76 | IAPP (0.53) | IAPPTDP1F2RL1 | |
| SCHEMBL4423244 | 0.76 | CYP4F2 (0.57) | TDP1TBXAS1L3MBTL1CYP1A2CYP3A4 | |
| SCHEMBL17983732 | 0.75 | CAPN1 (0.46) | HCAR2TBXAS1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL7013456 | 0.74 | CYP11B1 (0.46) | TBXAS1 | |
| SCHEMBL6298405 | 0.74 | HCAR2 (0.34) | HCAR2TBXAS1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL20665299 | 0.74 | CYP24A1 (0.40) | HCAR2TBXAS1L3MBTL1CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200331870-A1 | MCL-1 INHIBITORS | GILEAD SCIENCES, INC. | 2020-10-22 | — | — | US | disclosed |
| US-20190352271-A1 | MCL-1 INHIBITORS | GILEAD SCIENCES, INC. | 2019-11-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190352271-A1 | MCL-1 INHIBITORS | MCL1, BCL2L1, BCL2 | IAPP 2965/4885HCAR2 4611/4885TDP1 764/4885 |
| US-20200331870-A1 | MCL-1 INHIBITORS | MCL1, BCL2L1, BCL2 | IAPP 2965/4885HCAR2 4611/4885TDP1 764/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.